Clinical Case Analysis: Mixed Connective Tissue Disease (MCTD) with PAH

Diagnosis

Explaining the Clinical Course

Why she deteriorated on Methotrexate + Leflunomide + Methylprednisolone:

• Weight loss and anorexia - nausea, stomatitis, hepatotoxicity, and anorexia are among the most common adverse effects of methotrexate
• Oral ulcers - may have been worsened by methotrexate (folic acid antagonism)
• Psychiatric disturbances / irritability - methotrexate neurotoxicity is documented; leflunomide can also contribute

Current Management Assessment

What is appropriate currently:

Recommended Management Strategy

1. Disease-Modifying Treatment for MCTD (currently NOT on any DMARD)

• Hydroxychloroquine (HCQ) is the cornerstone of MCTD treatment - used in 85.8% of patients
• HCQ at diagnosis was associated with significantly less development of ILD or PAH (p<0.05)
• HCQ + low-dose glucocorticoids were sufficient to control disease in ~50% of patients
• DMARDs/IS were escalated for PAH and musculoskeletal involvement

2. PAH Management

• Optimize sildenafil - standard dosing for PAH is 20 mg TID (not 50 mg once), though dosing varies
• Consider adding an endothelin receptor antagonist (ERA) such as ambrisentan or macitentan for combination therapy, as PAH in CTD tends to be progressive
• Anti-coagulation consideration - PAH in CTD carries thrombotic risk (discuss risk/benefit given her age)
• Periodic RHC (right heart catheterization) to classify hemodynamic severity

3. Address the Anemia (Hb 7.8 g/dL)

• Normal creatinine (excludes renal cause)
• Normal WBC and platelets (not aplastic or drug-induced pancytopenia)
• Active MCTD with inflammatory burden

• Reticulocyte count, peripheral smear
• Serum iron, ferritin, TIBC (distinguish ACD from iron deficiency)
• Coombs test (rule out autoimmune hemolytic anemia - occurs in MCTD/SLE overlap)
• B12 and folate (especially important given prior methotrexate use, which depletes folate)

4. Low-dose Corticosteroid - Judicious Re-introduction if Needed

• Low-dose prednisolone (5-10 mg/day), not methylprednisolone
• Only if active inflammatory features (myositis, serositis, acute arthritis) are present
• With bisphosphonate bone protection
• Short course, tapering rapidly once disease controlled

5. Monitoring

6. If Disease Remains Refractory

• Rituximab (anti-CD20) - evidence in MCTD, especially for thrombocytopenia and refractory disease. Response rate ~80% for thrombocytopenic complications (Andrews' Diseases of the Skin)
• Azathioprine - better GI tolerability than methotrexate/leflunomide, safer alternative if immunosuppression needed for ILD
• Mycophenolate mofetil - increasingly used for CTD-PAH and CTD-ILD

Summary of Key Clinical Points

1. The diagnosis is MCTD - post-partum onset, anti-U1RNP+, RA factor+, multi-system involvement, PAH as the most serious complication
2. The prior drug regimen caused her side effects - methotrexate/leflunomide/high-dose steroids caused anorexia, weight loss, and psychiatric disturbances; stopping them appropriately improved symptoms
3. She is currently under-treated for MCTD - sildenafil addresses PAH but she needs a disease-modifying agent (HCQ is the best choice to restart) to reduce overall inflammation and potentially slow PAH progression
4. PAH requires escalation - moderate PAH in CTD typically needs combination therapy (PDE5i + ERA); single-agent sildenafil may be insufficient long-term
5. Anemia needs work-up - with Hb 7.8, a complete anemia panel including Coombs test is mandatory before attributing to ACD
6. Her psychiatricfeatures may be organic MCTD (CNS involvement) or drug-induced - now that steroids are off, if psychiatric symptoms recur, MCTD neuropsychiatric involvement should be considered and treated cautiously

• Murray & Nadel's Textbook of Respiratory Medicine, p. 2101
• Brenner and Rector's The Kidney, p. 1467
• Andrews' Diseases of the Skin, p. 293
• Robbins & Kumar Pathologic Basis of Disease, p. 223

Critical Appraisal of Your Current Regimen

✅ Hydroxychloroquine 200 mg BD (400 mg/day)

✅ Colchicine 0.6 mg BD

• Pericarditis/serositis in CTD/lupus
• Recurrent febrile episodes (acts on inflammasome/IL-1 pathway)
• Oral ulcers (off-label but evidence-supported)

⚠️ Nimesulide (NSAID) - Use with Caution / Reconsider

1. PAH + NSAID = Dangerous combination. NSAIDs cause sodium and water retention, increase systemic vascular resistance, and can precipitate right heart decompensation in PAH patients. In a patient already on noradrenaline (suggesting haemodynamic compromise), adding a vasoconstrictive/fluid-retaining agent is counterproductive.
2. Nimesulide is hepatotoxic - it carries a black box warning in several countries for idiosyncratic hepatotoxicity. In a patient on multiple drugs (HCQ, potentially immunosuppressed), this is an added risk.
3. NSAIDs are relatively contraindicated in SLE/MCTD overlap due to risk of aseptic meningitis, renal impairment, and fluid retention worsening cardiac status.
4. Better alternatives for fever/pain in MCTD: Paracetamol (acetaminophen) is safer for acute symptom relief. If serositis pain is the indication, colchicine (already given) + low-dose prednisolone are more appropriate.

⚠️ Inj. Methylprednisolone 250 mg IV (Pulse) - Justified but Monitor Carefully

• High-grade fever
• Tachycardia + tachypnoea
• Oral ulcers suggesting active mucosal disease
• Possible serositis/myocarditis

• Monitor for acute corticosteroid-induced psychosis post-pulse
• Do not continue high-dose steroids beyond the acute phase
• Transition to low-dose oral prednisolone (5-10 mg/day) after the pulse, not repeat high doses
• The psychiatric symptoms she developed previously were almost certainly steroid-induced, so minimize duration aggressively

🔴 Noradrenaline (Norepinephrine) 2 ml/hr Single Strength - Most Concerning Agent

• Alpha-1 stimulation raises systemic vascular resistance (SVR) - which is the intended effect to maintain coronary perfusion pressure
• However, it can also raise pulmonary vascular resistance (PVR), worsening right heart afterload
• The RV in PAH is already pressure-overloaded - increased afterload from a vasoconstrictor can precipitate complete RV failure

• The RV in decompensated PAH is dilated and underperfused
• Systemic hypotension reduces coronary perfusion to the RV (which is now perfused in both systole AND diastole)
• Maintaining MAP ≥65 mmHg with noradrenaline restores RV coronary perfusion and can actually improve RV function
• Per Giannakoulas et al. (Eur Heart J 2025, PMID 40259766): In acute RV failure, maintaining systemic pressure with vasopressors is necessary to prevent RV ischaemia

• Decompensated PAH/RV failure - norad + continue sildenafil + consider inhaled nitric oxide or nebulised iloprost
• Septic shock (she has fever, possible infection) - treat the underlying infection aggressively; norad appropriate but source control needed
• Drug-induced (was she on vasodilators that caused hypotension?) - review all medications

✅ Inj. Furosemide (Lasix) 10 mg IV - Appropriate but Needs Careful Titration

• Do not over-diurese - the RV in PAH is preload-dependent. Aggressive diuresis drops filling pressure and can worsen cardiac output further
• Target: relieve venous congestion (reduce JVP, peripheral oedema) without dropping BP
• Monitor urine output, creatinine, and electrolytes closely - hypokalaemia from furosemide + noradrenaline-driven tachycardia = arrhythmia risk

⚠️ Tab. Fluconazole 200 mg Stat - Indication Needs Justification

1. Oral candidiasis - her oral ulcers and prior steroid/immunosuppressive exposure put her at risk for oropharyngeal candidiasis. If the ulcers include thrush, a stat dose is reasonable.
2. Prophylaxis in an immunocompromised patient starting steroids - acceptable practice
3. Suspected systemic fungal infection - 200 mg stat is grossly underdosed for systemic candidiasis (requires loading 800 mg then 400 mg daily)

• Colchicine (CYP3A4 substrate) - risk of colchicine toxicity (myopathy, neuropathy, bone marrow suppression). This combination needs close monitoring or colchicine dose reduction.
• Sildenafil (CYP3A4 substrate) - can increase sildenafil levels by ~2-3x, risking hypotension

Summary Table

Most Urgent Questions to Address Right Now

1. Why is she on noradrenaline? What is her current BP/MAP? Is she in frank shock or borderline? This determines whether she needs ICU-level care.
2. Is the fever infective or disease flare? Blood cultures, procalcitonin, and urine culture are mandatory before escalating immunosuppression further. Giving IV methylprednisolone in uncontrolled sepsis can be fatal.
3. Has PE been ruled out? PAH + dilated RV + acute decompensation + tachycardia - acute pulmonary embolism must be excluded with CTPA or V/Q scan urgently, as this would completely change management.
4. Has sildenafil been continued through this acute admission? Never stop PAH-specific therapy during hospitalisation.

PAH: Full Investigations & Treatment Strategy for This Patient

PART 1 - Complete Investigation Workup for PAH

A. Confirming the Diagnosis - Mandatory Investigations

Critical note: RHC is mandatory before intensifying PAH therapy. Her 2D echo shows "moderate PAH" but echo-estimated RVSP can be inaccurate. Only RHC gives true mPAP, PAWP, and PVR - without which you cannot confirm Group 1 PAH vs Group 2 (left heart disease) or Group 3 (lung disease). - Braunwald's Heart Disease, p. 1007

B. Workup to Classify Group and Identify Comorbidities

C. Prognostic / Risk Stratification Labs

D. Cardiac MRI (if available)

PART 2 - WHO/NYHA Risk Classification Before Choosing Therapy

PART 3 - Treatment: Is Tadalafil + Ambrisentan the Right Choice?

Short Answer: YES - This is evidence-based first-line combination therapy for CTD-PAH, and is strongly supported.

The AMBITION Trial Evidence

• Design: Treatment-naïve PAH patients (n=500), randomized to:
  • Ambrisentan + Tadalafil combination
  • Ambrisentan monotherapy
  • Tadalafil monotherapy
• Primary endpoint: Composite of death, hospitalization for PAH, disease progression, or unsatisfactory clinical response
• Result at median 517 days:
  • Combination: 18% reached primary endpoint
  • Ambrisentan mono: 34%
  • Tadalafil mono: 28%
  • Combination = 50% hazard reduction vs. pooled monotherapy (HR 0.50, p<0.001)
• CTD-PAH subgroup: A dedicated subgroup analysis of the AMBITION trial for CTD-associated PAH confirmed the same benefit, making this directly applicable to your MCTD patient.

"The AMBITION trial demonstrated a clear benefit in hard-clinical events among incident, treatment-naïve PAH patients administered combination ambrisentan plus tadalafil compared with monotherapy with either agent." - Braunwald's Heart Disease, p. 1008

"The role of early, aggressive therapy with combination oral treatments was addressed in the landmark AMBITION trial." - Harrison's Principles of Internal Medicine 22E, 2025

Drug Dosing for This Patient

What About Sildenafil vs. Tadalafil?

ERA Choice: Ambrisentan vs. Macitentan vs. Bosentan

Triple Therapy - When to Consider

• Selexipag (oral IP receptor agonist) - GRIPHON trial showed 40% reduction in composite events
• Inhaled treprostinil - add-on to PDE5i + ERA
• Sotatercept (newest agent) - activin receptor II inhibitor; STELLAR trial (Phase 3 RCT, 2023) showed +40m improvement in 6MWD on top of background dual/triple therapy, with 60% of patients already on triple therapy in the trial (PMID 38012534, 39884760). FDA approved 2024. This is the most exciting development in PAH therapy in a decade.

Summary: Recommended PAH Management Plan

STEP 1 - Investigations (before escalating therapy)
   ├── RHC with vasoreactivity testing (mandatory)
   ├── V/Q scan (exclude CTEPH)
   ├── NT-proBNP + 6MWD (risk stratification)
   ├── HRCT chest (exclude ILD)
   ├── APLA panel (MCTD-SLE overlap)
   ├── LFT, TFT, HIV, Hep B/C
   └── Cardiac MRI (if available)

STEP 2 - First-Line Therapy (intermediate-risk CTD-PAH)
   ├── STOP sildenafil 50 mg OD (non-standard dosing)
   ├── START tadalafil 40 mg OD  ← PDE5 inhibitor
   └── START ambrisentan 5 mg OD → uptitrate to 10 mg at 4 weeks ← ERA
                                 [= AMBITION regimen, 50% HR reduction]

STEP 3 - If high-risk features (NYHA IV, CI <2.0, low 6MWD)
   └── Add prostacyclin (parenteral epoprostenol or inhaled iloprost)
       or refer for IV/SC treprostinil

STEP 4 - If suboptimal response at 6 months
   └── Consider adding sotatercept (STELLAR trial, 2023-24)
       or selexipag (GRIPHON trial)

STEP 5 - Supportive
   ├── Diuretics (furosemide ± spironolactone) for fluid overload
   ├── Supplemental O2 if SpO2 <92%
   ├── Digoxin if RV failure + low CO (increases CO by ~10%)
   ├── Treat anaemia (Hb 7.8 is significant - target Hb >12)
   ├── Vaccinations (influenza, pneumococcal)
   └── Supervised exercise rehabilitation

STEP 6 - Long-term
   └── Bilateral lung transplant evaluation if failing maximal medical therapy

Key Point for This Specific Patient

• Harrison's Principles of Internal Medicine 22E (2025), p. 2237
• Braunwald's Heart Disease, p. 1007-1008
• AMBITION trial: Galiè N et al. NEJM 2015; PMID 26303624
• STELLAR/sotatercept: Hoeper MM et al. Eur Respir J 2025 (PMID 39884760)

Splenic Abscesses in This Patient - A Critical Finding That Changes Everything

Why This Discovery is a Game-Changer

• The IV methylprednisolone you gave may have been the wrong move (steroids blunt the immune response needed to fight this infection)
• The noradrenaline requirement suggests she may be in septic shock from the abscesses, not purely cardiogenic shock from PAH
• The fluconazole stat dose may actually have been prescient - fungal splenic abscess is well-recognised in immunosuppressed patients

Understanding the Splenic Abscesses in Context

Why She Got Them - Risk Factors All Present

Microbiology - What Organisms Are Likely?

STEP 1: Urgent Investigations Needed NOW

Microbiological Workup (Priority)

Imaging

STEP 2: Treatment Decision for the Abscesses

The Critical Question: Drain vs Antibiotics Alone vs Splenectomy?

• These are microabscesses - too small to drain percutaneously (PCD generally requires >3-4 cm abscess)
• PCD is actually relatively contraindicated for multiple small abscesses (StatPearls, NCBI Bookshelf)
• Conservative management with targeted IV antibiotics + antifungals is the appropriate initial strategy
• Monitor with serial imaging (ultrasound every 5-7 days) to ensure no enlargement
• If any abscess enlarges beyond 3-4 cm or she deteriorates - escalate to PCD or splenectomy

STEP 3: Empirical Antimicrobial Regimen

If Bacterial Abscess Suspected (Clinical Sepsis)

Piperacillin-tazobactam 4.5g IV q6h
  OR
Meropenem 1g IV q8h (if severe sepsis/shock, prior antibiotics, hospital-acquired)

If Fungal Abscess Suspected (Multiple Small Abscesses + Immunosuppressed)

Micafungin 100 mg IV OD   ← echinocandin preferred in Candida
  OR
Caspofungin 70 mg IV loading, then 50 mg IV OD

1. Better efficacy in severely ill patients
2. No CYP interaction concerns with sildenafil/colchicine
3. Active against Candida glabrata and Candida krusei which may be fluconazole-resistant in steroid-exposed patients

If Mycobacterial Infection Suspected (not improving in 1-2 weeks)

STEP 4: Immediate Drug Changes in Her Current Regimen

STEP 5: Source Control and Surgical Consultation

• Refer to surgery + interventional radiology now for assessment
• Surgery should be on standby in case:
  • Abscesses enlarge or coalesce
  • Splenic rupture (catastrophic emergency in PAH patients)
  • She fails to respond to 5-7 days of medical therapy
• Get Infectious Disease consultation - complex host (MCTD + PAH + steroids) with rare infection

Summary - The Revised Clinical Picture

MCTD (underlying) 
  └── PAH (complication - moderate, dilated RA/RV on echo)
  └── Splenic abscesses x3 (NEW finding - likely the PRIMARY driver 
       of her current presentation: fever, tachycardia, tachypnoea, 
       weight loss, anorexia, haemodynamic instability)
       └── Possible sources:
            ├── Hematogenous spread from prior bacteraemia
            ├── Fungal (Candida) - most likely given multiple small 
            │   lesions + prior steroids + immunosuppressives
            └── Embolic from endocarditis (must be excluded by echo)

1. 🔴 Control the infection - blood cultures, empirical broad-spectrum antibiotics + antifungals, serial imaging
2. 🔴 Exclude endocarditis - echocardiogram (TTE/TEE)
3. 🟡 Stabilise haemodynamics - noradrenaline titration, continue sildenafil, careful diuresis
4. 🟡 Treat anaemia - Hb 7.8 is particularly dangerous in the context of sepsis + PAH
5. 🟢 MCTD/PAH long-term management - tadalafil + ambrisentan can be planned once infection is controlled and the patient is stabilised

• Radcliffe et al. Open Forum Infect Dis 2022 (PMID 35299986)
• Sánchez Martínez et al. Cureus 2025 (PMID 40391182) - splenic abscess + chronic corticosteroid use
• StatPearls: Splenic Abscess (NCBI Bookshelf, updated 2024)
• Gutama et al. Surg Infect 2022 - Splenectomy vs PCD systematic review

Hydrocortisone 50 mg QID in This Patient: A Complex but Defensible Decision - With Important Caveats

Understanding What 50 mg QID Actually Is

Two Possible Rationales - Only ONE is Correct Here

Rationale 1 (WRONG in this patient): "Give steroids to suppress MCTD fever"

• Dangerous - it will further suppress neutrophil function, macrophage activity, and T-cell responses that are already compromised
• Counterproductive - the splenic abscesses will grow, potentially coalesce, and risk rupture
• Evidence-contradicted - multiple textbooks and guidelines caution against immunosuppressive steroids in uncontrolled focal infection

Rationale 2 (POTENTIALLY VALID): "She has CIRCI (Critical Illness-Related Corticosteroid Insufficiency)"

The Core Problem: You CANNOT Distinguish MCTD Fever from Septic Fever Without Data

What the Evidence Actually Says About Steroids in This Setting

For (supporting the hydrocortisone):

1. Surviving Sepsis Campaign 2021: Recommends hydrocortisone 200 mg/day IV for septic shock not responding to fluids + vasopressors (she is on noradrenaline - this criterion is met)
2. APROCCHSS trial (2018): Hydrocortisone 200 mg/day + fludrocortisone reduced 90-day mortality in vasopressor-dependent septic shock
3. Prior steroid use = very likely HPA axis suppression = she may be genuinely cortisol-insufficient, making stress-dose replacement medically necessary
4. Duration reduction: Even if mortality benefit is inconsistent, steroids consistently reduce duration of vasopressor requirement and shock (multiple RCTs, meta-analyses)

Against (concerns):

1. Active splenic abscesses - steroids impair neutrophil chemotaxis, macrophage phagocytosis, and lymphocyte function - all needed to contain the abscesses
2. Fungal risk - she already has a pattern of multiple small abscesses highly suggestive of fungal origin; steroids dramatically increase the risk of fungal dissemination
3. Hyperglycaemia - steroids cause stress hyperglycaemia, which worsens infection outcomes and endothelial function in PAH
4. Psychiatric history - she has already demonstrated steroid-induced psychiatric disturbances; reintroduction risks recurrence

The Bottom Line: Conditional Acceptance With Mandatory Safeguards

Mandatory conditions that must be met simultaneously:

• Ensure IV echinocandin (micafungin/caspofungin) is already running alongside the hydrocortisone
• β-D-glucan and fungal blood cultures must already be sent

• Stress-dose hydrocortisone should be weaned as soon as vasopressors are being weaned
• SSC guideline: taper when vasopressor dose is decreasing, not on a fixed calendar
• Do not continue beyond vasopressor requirement
• Rosen's EM: "High-dose, short-course corticosteroid therapy... potential risks of secondary infection and GI bleeding"

• Hydrocortisone causes significant steroid hyperglycaemia
• Target blood glucose 6-10 mmol/L (110-180 mg/dL) with insulin infusion if needed

• If PCT >2 ng/mL = sepsis is driving the fever, NOT MCTD; steroids are only justified as CIRCI treatment
• If PCT <0.5 ng/mL = infection is less likely; reconsider whether steroids are appropriate at all

• She has previously developed severe irritability and psychiatric disturbances on methylprednisolone
• Hydrocortisone is less likely to cause psychiatric effects than methylprednisolone (less CNS penetration, no fluorine group), but it can still do so
• Daily mental status assessment

• The older Annane trial used hydrocortisone + fludrocortisone 50 mcg/day; this is not routinely recommended unless adrenal insufficiency is confirmed

Fever Management Alongside Hydrocortisone

Summary Decision Framework

Is she vasopressor-dependent (noradrenaline running)?
         ↓ YES
Has she had prior chronic steroid use (HPA suppression risk)?
         ↓ YES
Is she failing to respond to fluids + vasopressors?
         ↓ YES
         
→ Hydrocortisone 200 mg/day (50 mg QID) is GUIDELINE-SUPPORTED
  as stress-dose for CIRCI / vasopressor-dependent septic shock
  
BUT mandatory conditions:
  ✓ Ensure IV antifungal cover (echinocandin) is running
  ✓ Send procalcitonin, β-D-glucan, blood cultures NOW if not done
  ✓ Strict blood glucose monitoring
  ✓ Wean hydrocortisone when vasopressors are being weaned
  ✓ Do NOT continue steroids for fever control after vasopressors stopped
  ✓ Psychiatric monitoring
  ✓ Serial splenic imaging in 5-7 days to ensure abscesses not enlarging

• Sabiston Textbook of Surgery, p. 327 - CIRCI and stress-dose steroids
• Rosen's Emergency Medicine, p. 1734 - hydrocortisone in refractory shock
• Current Surgical Therapy 14e, p. 1485 - SSC guidelines, hydrocortisone 200 mg/day
• Fowler et al. J Intensive Care Med 2023 (PMID 37365820) - CIRCI review

Biomarker Interpretation - This is the Most Important Data Yet

THE OVERALL PICTURE IN ONE SENTENCE

CRP elevated + Procalcitonin normal + Troponin elevated + NT-proBNP elevated + D-dimer elevated = Active inflammatory/autoimmune process driving PAH-related right heart strain, with probable fungal (not bacterial) splenic abscesses - NOT bacterial sepsis.

1. Procalcitonin <0.15 ng/mL - The Most Important Result

What normal PCT tells you:

• PCT in candidaemia: median 0.29 ng/mL (IQR 0.14-0.69) - frequently <0.5
• PCT in gram-negative bacteraemia: median 1.73 ng/mL (IQR 0.5-6.9), p<0.001
• PCT in gram-positive bacteraemia: median 0.51-1.3 ng/mL

• No systemic infection at all (sterile inflammation)
• Localised fungal infection not yet causing candidaemia (i.e., contained splenic fungal abscesses without bloodstream dissemination)
• Pure MCTD disease flare activity

What this means for current management:

• The noradrenaline and hydrocortisone cannot be justified as "septic shock management" with a PCT <0.15. The haemodynamic instability is more likely cardiogenic (PAH + RV failure) than septic
• Broad-spectrum antibiotics (piperacillin-tazobactam, meropenem) can be de-escalated or reconsidered - there is no PCT evidence to support empirical antibacterial therapy
• Antifungal therapy should continue - low PCT does not exclude fungal disease and actually supports it
• Hydrocortisone should be reassessed - the CIRCI justification weakens if the patient is not in true septic shock; the cardiogenic/PAH component is more prominent

2. CRP 60 mg/L - Moderate Elevation

• Any inflammatory state - bacterial, viral, fungal, autoimmune, ischaemic
• Unlike PCT, CRP cannot distinguish infectious from non-infectious inflammation

• Active MCTD disease flare (CRP can be significantly elevated in CTD)
• Contained fungal abscess
• RV strain/myocardial injury (see troponin below)

CRP elevated + PCT normal = Think autoimmune disease activity or fungal infection, not bacterial sepsis.

3. NT-proBNP 1500 pg/mL - HIGH RISK Threshold

ESC/ERS 2022 PAH Risk Stratification (incorporated in Harrison's 22E):

1. Her RV is significantly stressed - the PAH is haemodynamically significant, not just incidental
2. Without escalation of PAH therapy, her prognosis is poor (5-year survival <40% in high-risk PAH)
3. This is a major indication to escalate from sildenafil monotherapy to combination tadalafil + ambrisentan - reinforcing the treatment plan already discussed
4. The NT-proBNP also explains the haemodynamic instability (noradrenaline requirement) - this is RV failure from PAH contributing significantly alongside any septic component

4. Troponin I 69 ng/L - RV Myocardial Injury

Why troponin rises in PAH:

• NOT the same as an ACS (myocardial infarction) - do NOT treat as STEMI/NSTEMI
• IS a marker of RV strain and impending RV failure
• A troponin of 69 ng/L (Troponin I) in PAH = intermediate-to-high risk feature in PAH risk stratification

What troponin 69 tells you clinically:

1. The RV is ischaemic/stressed right now - this is urgent
2. Maintain MAP ≥65 mmHg to preserve RV coronary perfusion (justifies the noradrenaline from a cardiac standpoint, even if septic shock is less likely)
3. Maintain sildenafil/PAH therapy - reducing pulmonary vascular resistance reduces RV afterload and will help bring troponin down
4. Avoid tachycardia - the RV in PAH is rate-sensitive; tachycardia reduces diastolic filling time and worsens RV ischaemia. If tachycardia is present, treating the underlying cause (fever, pain, volume status) is critical
5. Avoid vasodilators that drop systemic BP further - maintaining coronary perfusion to the RV is the priority

5. D-Dimer 1300 ng/mL (or μg/L FEU) - Elevated but Non-Specific

What elevates D-dimer in this patient:

Integrated Biomarker Summary

Revised Management Priorities Based on These Results

1. RECONSIDER hydrocortisone 50mg QID
   → PCT <0.15 argues against true septic shock as the primary driver
   → RV failure from PAH (NT-proBNP 1500, Troponin 69) is likely the 
      dominant cause of haemodynamic instability
   → If noradrenaline is still running, hydrocortisone may be justified 
      as CIRCI (prior steroid use = HPA suppression), but not as 
      anti-inflammatory therapy for MCTD

2. ESCALATE PAH therapy NOW (NT-proBNP 1500 = HIGH RISK)
   → Switch sildenafil → Tadalafil 40 mg OD
   → Add Ambrisentan 5 mg OD
   → Target NT-proBNP <300 as treatment response marker

3. CONTINUE antifungals (low PCT supports fungal, not bacterial)
   → IV echinocandin (micafungin/caspofungin)
   → β-D-glucan result awaited
   → Blood cultures (fungal) result awaited

4. DE-ESCALATE or STOP broad-spectrum antibiotics
   → PCT <0.15 = no bacterial sepsis evidence
   → Wait for blood culture results before continuing empirical antibacterials

5. SERIAL MONITORING
   → Troponin repeat in 12-24 hours (RV trajectory)
   → NT-proBNP repeat in 48-72 hours (PAH response)
   → PCT repeat in 24-48 hours (if fever persists, rule out late bacterial superinfection)

6. SEND APLA PANEL (D-dimer 1300 + MCTD/SLE overlap)
   → Anticardiolipin IgG/IgM, anti-β2GPI, lupus anticoagulant

Lactate 2.5 mmol/L - What This Means and Why It Changes Management

The Number in Context

The Sepsis-3 Significance

Sepsis + vasopressor requirement to maintain MAP ≥65 mmHg + serum lactate >2 mmol/L despite adequate fluid resuscitation

• ✅ Vasopressors (noradrenaline 2 ml/hr)
• ✅ Lactate 2.5 mmol/L (>2 mmol/L)
• Possible infection (splenic abscesses)

• Lactate >2.5 mmol/L: 28-day mortality 16.9% vs 5.8% for lactate ≤2.5 (RR 2.93, p<0.001)
• The combination of hyperlactatemia (>2.5) + vasopressor need ("dysoxic/tissue dysoxic shock"): 44.8% 28-day mortality in the Ranzani cohort

But Here Is the Critical Distinction: WHY is the Lactate Elevated?

1. Cardiogenic Tissue Hypoperfusion (PRIMARY driver - most likely)

• NT-proBNP 1500 pg/mL (HIGH RISK) = severe RV pressure overload
• Troponin I 69 ng/L = RV myocardial ischaemia
• Dilated RA + RV on echo = RV failure with reduced forward output
• PAH + noradrenaline requirement = cardiogenic shock physiology

2. Anaemia-Related (Contributing)

3. Sepsis/Fungal Infection (Possible but less likely primary driver given PCT <0.15)

The Lactate in Combination with All Other Biomarkers

What the Lactate of 2.5 Changes in Management

1. Justifies continuing noradrenaline - but for the RIGHT reason

2. Hydrocortisone is now more justifiable - but dose matters

• Stress-dose replacement for CIRCI
• May help wean vasopressors sooner (the primary evidence-based endpoint)

3. Serial lactate clearance is now the most important monitoring parameter

4. The single most impactful intervention for lactate clearance

5. Correct the anaemia

The Complete Integrated Picture Now

MCTD (underlying autoimmune disease)
    │
    ├── PAH (Group 1, CTD-associated)
    │     ├── NT-proBNP 1500 = HIGH RISK
    │     ├── Troponin 69 = RV ischaemia
    │     └── Dilated RA/RV on echo
    │           │
    │           └── RV FAILURE → Low cardiac output
    │                               → Lactate 2.5 mmol/L (cardiogenic)
    │                               → Hepatic congestion (impaired lactate clearance)
    │                               → Haemodynamic instability (noradrenaline running)
    │
    ├── Splenic abscesses x3 (probable fungal - PCT <0.15, multiple small lesions)
    │     └── Contributing to CRP 60, D-dimer 1300, fever
    │         (NOT the primary cause of lactate or haemodynamic instability)
    │
    └── Anaemia Hb 7.8
          └── Reducing DO₂ → amplifying lactate from RV failure

BOTTOM LINE: This is predominantly CARDIOGENIC shock from decompensated
PAH/RV failure + anaemia, with a fungal infectious co-morbidity.
The lactate will not clear until RV afterload is reduced.

Immediate Priority Action List

Anti-SSA + Anti-Ro52 3+ Positive: Diagnostic and Clinical Implications

What You Now Have - The Full Antibody Profile

Understanding Anti-SSA vs Anti-Ro52 - They Are DIFFERENT Antigens

What Anti-SSA (Ro60) 3+ Tells You

1. Sjögren's Syndrome Overlap (Primary or Secondary)

• Dry eyes (xerophthalmia) - gritty, burning sensation
• Dry mouth (xerostomia) - difficulty swallowing dry food, dental caries
• Parotid gland swelling
• Vaginal dryness
• Peripheral neuropathy

2. PAH Risk in Sjögren's

3. Cardiac Conduction - Neonatal Lupus Risk

What Anti-Ro52 (TRIM21) 3+ Tells You - The Most Important New Information

1. Severe ILD Risk

• In CTD-ILD patients: anti-Ro52 positive patients had significantly lower FVC% (p=0.004), more respiratory symptoms at baseline, and more organising pneumonia (OP) pattern on HRCT (Clin Exp Rheumatol)
• In antisynthetase syndrome: anti-Ro52 + anti-Jo1 co-positivity causes more severe ILD than anti-Jo1 alone (La Corte et al.)
• In myositis: anti-Ro52 + anti-MDA5 co-positivity predicts rapidly progressive ILD with very high mortality
• In SSc: anti-Ro52/TRIM21 independently associated with ILD presence and poor survival

2. PAH + ILD Overlap - Worst Prognosis Category

"PH dramatically and independently impacts prognosis of patients with IM-ILD; the survival of AS-associated ILD with PH is far lower than that of ILD alone."

3. Myositis / Inflammatory Muscle Disease Component

• Check CK (creatine kinase) - if elevated, she has an occult myositis component
• Check Aldolase
• Consider EMG and muscle MRI if CK elevated
• Anti-Jo1 (anti-histidyl tRNA synthetase) should be checked - this is the defining antibody of antisynthetase syndrome, which is characterised by: myositis + ILD + arthritis + mechanic's hands + Raynaud's + fever = she has multiple features

Revised Diagnostic Framework: Complex CTD Overlap Syndrome

COMPLEX CTD OVERLAP SYNDROME

Core:
  ✅ MCTD (anti-U1RNP positive, high titre)
  ✅ Sjögren's syndrome overlap (anti-SSA/Ro60 3+, sicca symptoms likely present)
  ✅ Possible antisynthetase-like syndrome (anti-Ro52/TRIM21 3+)

Complications:
  ✅ PAH - Group 1 CTD-associated (HIGH RISK: NT-proBNP 1500)
  ⚠️  ILD - to be excluded urgently (anti-Ro52 3+ = high ILD risk, HRCT protocol needed)
  ✅ Haemolytic/inflammatory anaemia (Hb 7.8)
  ✅ Splenic abscesses (probable fungal, PCT <0.15)
  ⚠️  Myositis component - check CK/aldolase, anti-Jo1

Additional Investigations Now Required

How Anti-Ro52 Changes Treatment Planning

1. ILD assessment before finalising PAH treatment

• Ambrisentan is generally avoided in CTD-ILD-PH (ERA therapy can worsen ILD-related PH by causing pulmonary oedema in post-capillary components)
• Macitentan has better evidence in SSc-ILD-PH than ambrisentan
• Nintedanib (anti-fibrotic) is now indicated for ILD in multiple CTDs (approved for SSc-ILD, and increasingly used off-label for CTD-ILD broadly)
• Mycophenolate mofetil is the preferred immunosuppressant for CTD-ILD

2. Immunosuppression for ILD/myositis component

• Mycophenolate mofetil 1-3g/day (CTD-ILD first line, well tolerated)
• Azathioprine 2 mg/kg/day (alternative)
• IV rituximab if refractory (anti-Ro52 positive CTD-ILD shows good response to rituximab in some series)
• HCQ continues as backbone (already started - correct)

3. Sjögren's management

• Pilocarpine 5 mg TDS or cevimeline for sicca symptoms
• Artificial tears (preservative-free)
• Regular dental review (xerostomia → accelerated dental caries)
• HCQ (already on) is beneficial for systemic Sjögren's features

Summary: What Anti-SSA + Anti-Ro52 3+ Means for This Patient

Anti-CCP Negative: What This Confirms

The Short Answer

Understanding the RF Positive / Anti-CCP Negative Pattern

What This Does and Does Not Rule Out

Confirmed by anti-CCP negative:

• ✅ RA is NOT the primary diagnosis - she does not have rheumatoid arthritis
• ✅ The RF positivity is a feature of her CTD/Sjögren's overlap - not an RA-specific marker
• ✅ No joint erosions from RA expected - though MCTD can cause deforming non-erosive arthropathy (Jaccoud's-like)
• ✅ Methotrexate was likely over-prescribed - if the original treating doctor gave MTX thinking she had RA (because of positive RF), this was based on an incomplete serological picture

What remains unchanged:

• She still has MCTD (U1RNP positive - the defining antibody, unaffected by anti-CCP)
• She still has Sjögren's overlap (anti-SSA/Ro52 positive - unchanged)
• She still has RF positivity - but it is now correctly attributed to CTD, not RA
• The arthralgia/joint symptoms she has are from MCTD, not RA

The Complete Antibody Profile - Revised Interpretation

Clinical Implication for Treatment

Summary in One Paragraph

ANA Profile-3 (Immunoblot) - Full Report Analysis

Patient: Mrs. K Jyothi | Female, 27 years | Inodaya Hospitals, Kakinada

Complete Result Table

Critical Observation: Anti-RNP/Sm is NEGATIVE on This Panel

1. This panel tests Anti-RNP/Sm as a combined antigen

2. If anti-U1RNP is truly negative on re-testing

What the Report Definitively EXCLUDES

What the Report Positively Confirms

Anti-SS-A native (Ro60) intensity 53 = 3+

• The primary diagnostic antibody for Sjögren's syndrome
• Also found in SLE (but anti-dsDNA and anti-Sm are both negative, arguing against primary SLE)
• Found in MCTD with Sjögren's overlap (her likely diagnosis)
• Associated with photosensitivity, neonatal lupus, congenital heart block risk in pregnancies, and secondary sicca features

Anti-Ro52 (TRIM21) intensity 51 = 3+

• ILD (interstitial lung disease) - independently associated with more severe ILD in CTD
• Inflammatory myopathies - occurs frequently in IIM in the presence of ILD
• Antisynthetase-like features even when anti-Jo-1 is negative (non-Jo-1 antisynthetase or isolated Ro52 overlap)
• Worse prognosis in CTD-ILD

The Dual Ro60 + Ro52 Positivity Pattern

• Primary Sjögren's syndrome with systemic/extraglandular involvement - dual Ro60+Ro52 positivity is more strongly associated with systemic Sjögren's than Ro60 alone
• Sjögren's-MCTD overlap - when combined with her positive U1RNP
• A subgroup of Sjögren's patients with severe pulmonary manifestations including ILD and PAH

Revised Diagnostic Synthesis

FINAL SEROLOGICAL PICTURE:

POSITIVE:                           NEGATIVE (all others):
✅ Anti-SSA/Ro60 (3+, intensity 53) ❌ Anti-Sm (SLE excluded)
✅ Anti-Ro52/TRIM21 (3+, intensity 51) ❌ Anti-dsDNA (SLE excluded)
✅ Anti-U1RNP (prior test - positive) ❌ Anti-Jo-1 (classic ASS excluded)
✅ RF positive                       ❌ Anti-Scl-70 (dcSSc excluded)
❌ Anti-CCP (RA excluded)            ❌ Anti-La/SSB (isolated pSS excluded)
                                     ❌ Anti-Centromere (CREST excluded)
                                     ❌ Anti-Histone (drug lupus excluded)
                                     ❌ AMA-M2 (PBC excluded)

DIAGNOSIS:
Primary: SJÖGREN'S SYNDROME (secondary/overlap type)
         with MCTD features (if U1RNP confirmed positive)
         ± Undifferentiated CTD / overlap syndrome

Complications:
  - PAH (Group 1 CTD-associated, HIGH RISK: NT-proBNP 1500)
  - ILD to be excluded (Ro52 3+ = HIGH ILD RISK - HRCT mandatory)
  - Anaemia (Hb 7.8 - inflammatory/autoimmune)
  - Splenic abscesses x3 (probable fungal)

What This Panel Does NOT Include - Gaps to Fill

What Page 2-5 of the Report Might Contain

• Myositis-specific antibody panel (anti-Mi-2, MDA5, TIF1-γ, NXP2, SAE1, SRP)
• Anti-phospholipid antibodies
• Complement levels (C3, C4)
• Other extended ENA specificities

Management Implication from This Report

PAH Treatment: ILD Present vs ILD Absent - The Critical Difference

The Fundamental Difference: Group Classification

SCENARIO A: ILD ABSENT - Pure CTD-PAH (Group 1)

This is the ideal scenario - full Group 1 PAH algorithm applies

• 50% reduction in hazard for composite endpoint with dual therapy vs monotherapy
• Improved RV function, haemodynamics, 6MWD, and BNP in CTD-PAH specifically
• Real-world OPUS/OrPHeUS data 2024 confirm macitentan is also effective in CTD-PAH with good tolerability

Step 1: Tadalafil 40mg OD + Ambrisentan 10mg OD
   ↓ If suboptimal at 3-6 months (NT-proBNP not falling, 6MWD not improving)
Step 2: Add selexipag (prostacyclin IP receptor agonist)
   - GRIPHON trial: 40% reduction in composite morbidity/mortality
   ↓ If high-risk features (NYHA IV, CI <2.0, syncope, chest pain)
Step 3: IV/SC prostacyclin (epoprostenol or treprostinil) immediately
   ↓ Refractory to triple therapy
Step 4: Sotatercept (STELLAR trial: +40m 6MWD on top of background therapy)
   - FDA approved 2024; activin signalling inhibitor
   ↓ Maximal medical therapy failing
Step 5: Lung transplant evaluation

SCENARIO B: ILD PRESENT - PH-ILD (Group 3)

The situation changes completely - several drugs become harmful

• Blood flow is redistributed to poorly ventilated, damaged alveoli (hypoxic vasoconstriction is overcome)
• This causes ventilation-perfusion (V/Q) mismatch → profound hypoxia
• The patient paradoxically gets worse oxygenation despite improved pulmonary haemodynamics
• Additionally, ERA drugs can cause pulmonary oedema via post-capillary effects in diseased lungs

Drugs CONTRAINDICATED in significant ILD-PH:

"ERAs and riociguat should not be used in PH-ILD due to lack of efficacy and evidence for harm in the case of ambrisentan and riociguat." - Pulmonary Fibrosis Foundation Position Statement

"Neither ERAs nor riociguat is recommended in treatment of patients with ILD-PH due to safety concerns." - PMC10711418, CTD-PH comprehensive review 2023

The ONLY FDA-approved therapy for Group 3 PH-ILD:

• 326 patients with Group 3 PH-ILD (including 22.1% CTD-ILD)
• Inhaled treprostinil vs placebo, titrated to 9-12 breaths QID
• Primary endpoint met: +31.12 m improvement in 6MWD (95% CI 16.85-45.39, p<0.001)
• Improved NT-proBNP, time to clinical worsening
• Well tolerated - similar serious AE rates to placebo
• First and only FDA-approved therapy for Group 3 PH

THE KEY DECISION TREE FOR THIS PATIENT

HRCT result
    │
    ├── ILD ABSENT (or minimal, <10% lung involvement)
    │       └── PH is Group 1 CTD-PAH
    │               ↓
    │       TREAT WITH FULL GROUP 1 ALGORITHM:
    │       Tadalafil 40mg OD + Ambrisentan 5→10mg OD
    │       (AMBITION regimen - 50% HR reduction)
    │       Escalate to selexipag if needed
    │
    ├── ILD MILD (10-30% involvement) + PH SEVERE (NT-proBNP 1500 - her case)
    │       └── BORDERLINE - treat as Group 1 with monitoring
    │               ↓
    │       Consider tadalafil + ambrisentan BUT
    │       Monitor oxygenation closely after starting ERA
    │       If hypoxia worsens → switch to inhaled treprostinil approach
    │
    └── ILD SIGNIFICANT (>30-50% involvement)
            └── PH is predominantly Group 3
                    ↓
            ❌ DO NOT USE ambrisentan, bosentan, riociguat
            ✅ Inhaled treprostinil QID (INCREASE trial)
            ✅ Treat ILD: Nintedanib OR MMF
            ✅ O₂ supplementation
            ✅ Consider sildenafil with caution at expert centre
            ✅ Urgent lung transplant evaluation

Comparison Summary Table

Why This Matters Urgently for This Patient

• NT-proBNP 1500 = HIGH RISK → needs PAH therapy now, cannot wait
• Anti-Ro52 3+ = significant ILD risk in her antibody profile
• CTPA done → good at excluding PE, but not adequate for ILD assessment (needs thin-section HRCT)
• Planned treatment: Tadalafil + Ambrisentan → correct IF ILD absent or mild

1. Start tadalafil 40 mg OD now - PDE5i is acceptable in both Group 1 and Group 3 (lower harm risk than ERA)
2. Get HRCT within 24-48 hours
3. If ILD absent → add ambrisentan (AMBITION regimen)
4. If ILD significant → do NOT add ambrisentan; switch strategy to inhaled treprostinil + nintedanib + MMF

• CTD-PH Comprehensive Review, PMC10711418, 2023
• INCREASE trial: Waxman et al. NEJM 2021 (inhaled treprostinil in Group 3 PH)
• ARTEMIS-IPF trial (ambrisentan harm in ILD-PH)
• AMBITION trial: Galiè et al. NEJM 2015 (tadalafil + ambrisentan in Group 1 PAH)
• Pulmonary Fibrosis Foundation Position Statement on PH-ILD, 2023
• Kuwana et al. Ann Rheum Dis 2020 (AMBITION CTD-PAH subgroup)

Complete Report Analysis - Mrs. K Jyothi, 27F | 15/06/2026

CTPA Report (13/06/2026) - Full Interpretation

Confirmed findings:

CRITICAL CTPA LIMITATION - ILD Assessment:

2D Echo Report (15/06/2026) - Complete Interpretation

Structural Measurements:

The Key Findings:

• The cardiologist has documented RVSP of 63 mmHg
• In the absence of pulmonary valve stenosis: RVSP ≈ mPAP × 1.5 - 1.5
• 63 mmHg RVSP corresponds to estimated mPAP approximately 35-42 mmHg - well above the diagnostic threshold of >20 mmHg
• Combined with NT-proBNP 1500, troponin 69, dilated IVC → this is haemodynamically significant PAH

The Critical Paradox: "Increased PAH but Reduced TR"

Why reduced TR with worsening PAH is paradoxically dangerous:

1. Rising RV afterload → RV pressure overload
2. RV dilation → tricuspid annular dilation
3. Tricuspid leaflets fail to coapt → regurgitant jet develops

What this means specifically for her:

• RVSP 63 mmHg (measured from a mild TR jet)
• IVC 22mm, dilated and non-collapsing → RAP ≥15 mmHg
• Mildly dilated RA/RV (earlier echo had more severe dilation - this could reflect that the RV is no longer distending, it is starting to fail)
• Fair RV function (not normal - "fair" = borderline)
• LV EF 70% → LV is hyperdynamic, not the problem

"The absence of a significant TR jet does not indicate normal pulmonary pressures... The IVC diameter >21mm with <50% inspiratory collapse indicates significant elevation of right atrial pressure." - ACC

"Severe TR causes rapid RA-RV pressure equalisation - the pressure gradient driving the jet falls despite high RV pressure - leading to underestimation of RVSP." - Korean Circulation Journal 2024

IVC 22mm Non-Collapsing - What This Tells You

• If only 5 mmHg RAP assumed: RVSP = 63 mmHg
• If 15 mmHg RAP (as IVC suggests): true RVSP likely 70+ mmHg

LV EF 70% - Another Key Observation

• No LV systolic dysfunction contributing to PH (excludes Group 2 PH)
• LV is being compressed by the distended RV (interventricular dependence)
• The "no LV RWMA" confirms no ischaemia of the left side
• But note: diastolic function data is absent from this report - e:e' ratio and mitral inflow pattern are not documented. This matters because CTD can cause diastolic dysfunction contributing to pulmonary venous hypertension.

Handwritten Prescription at Bottom of Echo - What Was Prescribed

1. T. Tadalafil - 0.6 (?)  - 12
2. T. Ambrisentan - 2.4 (?) - 24
3. Inj. Lasix - 5mg - 24h

Updated Clinical Summary - 15/06/2026

IMAGING INTEGRATION:
┌─────────────────────────────────────────────────────────┐
│ CTPA (13/06): PE excluded ✅                            │
│              ILD: Cannot be assessed - NOT an HRCT      │
│              Splenic abscesses confirmed x3, ~1cc each  │
│              Minimal pericardial effusion 8mm           │
│              Basal atelectasis/dependent oedema         │
│                                                         │
│ ECHO (15/06): RVSP 63 mmHg (likely underestimate)       │
│              IVC 22mm non-collapsing → RAP ≥15 mmHg     │
│              Mild TR (reduces reliability of RVSP)      │
│              Fair RV function (NOT normal)              │
│              LV EF 70% (LV structurally normal)         │
│              Mildly dilated RA/RV                       │
│              Minimal pericardial effusion (post-LV)     │
│              No clot/vegetation (reassuring)            │
└─────────────────────────────────────────────────────────┘

HAEMODYNAMIC PROFILE:
- RVSP 63 mmHg + RAP 15 mmHg = severe RV afterload
- Lactate 2.5 = tissue hypoperfusion (cardiogenic)
- Troponin 69 = ongoing RV myocardial strain
- NT-proBNP 1500 = HIGH RISK category confirmed
- Noradrenaline ongoing = vasopressor-dependent

RISK STRATIFICATION: HIGH RISK PAH
(NT-proBNP >800, RVSP >50, RV dysfunction, vasopressor dependent,
troponin positive, lactate elevated = all high-risk criteria met)

Immediate Action Points From Today's Data

What "Reduced TR with Increased PAH" Tells You About Her Prognosis

CT Chest Plain (11/06/2026) - Full Analysis + Tadalafil Dose Correction

Part 1: CT Chest Report - Complete Interpretation

Full Findings Summary:

Part 2: The Critical Finding - "Multiple Fibrotic Bands, Bilateral Lower Lobe, Subpleural"

What this means - this IS early ILD

Important limitation of this CT:

• 0.625-1.25mm thin slices (vs 5mm here)
• Inspiration + expiration sequences
• Prone positioning for dependent atelectasis vs true ILD differentiation
• Multiplanar reconstructions

Classification: ILD IS PRESENT

CT Chest 11/06/2026 IMPRESSION:
"Multiple fibrotic bands, bilateral lower lobe, subpleural"

= EARLY CTD-ILD (NSIP pattern)
= Consistent with anti-Ro52 3+ / anti-SSA 3+ / MCTD-Sjögren's overlap
= ILD PRESENT - but extent needs dedicated HRCT (0.625mm slices)

Part 3: How This Changes the PAH Treatment Plan

What ILD present means for her PAH drugs:

The critical decision - is she Group 1 or Group 3?

• ILD is early/mild (bilateral lower lobe fibrotic bands only, no honeycombing, no traction bronchiectasis reported, no consolidation)
• PAH is severe (RVSP 63 mmHg, NT-proBNP 1500, troponin 69, IVC 22mm non-collapsing)
• The PAH severity is disproportionate to the apparent ILD extent

"Patients with mild ILD and significant PH are often treated according to the Group 1 treatment algorithm." - PMC10711418

1. Monitor oxygenation closely after starting ambrisentan - if SpO₂ drops, stop immediately
2. Start at lowest ambrisentan dose (2.5mg) - already written on the echo
3. Plan dedicated HRCT (thin-slice) to quantify true ILD extent - if >20-30% lung involvement, shift toward Group 3 approach
4. Nintedanib + MMF must be added for the ILD component once infection is cleared

Part 4: Tadalafil Dose - 20mg is SUBTHERAPEUTIC for PAH

• The erectile dysfunction dose (Cialis 20mg)
• The renal impairment starting dose (CrCl 31-50 mL/min: start 20mg, uptitrate to 40mg if tolerated)
• The dose used for BPH

However - a nuance for this specific patient:

• Continue tadalafil 20mg OD for 5-7 days while haemodynamics stabilise
• Uptitrate to 40mg OD as soon as noradrenaline is weaned or MAP is consistently ≥65 without dose escalation
• Do NOT remain on 20mg long-term - it is not the therapeutic PAH dose
• The AMBITION trial combination was tadalafil 40mg + ambrisentan 10mg - the full combination requires 40mg tadalafil to replicate trial outcomes

Part 5: Updated Complete Management Plan - 15/06/2026

CONFIRMED DIAGNOSES:
✅ CTD overlap syndrome (MCTD + Sjögren's, anti-U1RNP + anti-SSA 3+ + anti-Ro52 3+)
✅ Group 1 CTD-PAH, HIGH RISK (RVSP 63mmHg, NT-proBNP 1500, troponin 69)
✅ Early CTD-ILD (NSIP pattern - bilateral lower lobe subpleural fibrotic bands)
✅ Splenic abscesses x3 (~1cc, likely fungal - low PCT, multiple small lesions)
✅ Minimal pericardial effusion (developing between 11-13 June)
✅ RV failure compensated (fair RV function, IVC 22mm non-collapsing, lactate 2.5)

ACTIVE MEDICATIONS - STATUS:
PAH THERAPY:
  Tadalafil 20mg OD → ⚠️ SUBTHERAPEUTIC - uptitrate to 40mg OD when stable
  Ambrisentan 2.5mg OD → ✅ Acceptable start dose; monitor O₂ saturation
                         → ⚠️ Watch for hypoxia worsening (ILD present)

BACKGROUND CTD:
  HCQ 200mg BD → ✅ Continue
  Colchicine 0.6mg BD → ✅ Continue for serositis/fever

INFECTION:
  IV Echinocandin (micafungin/caspofungin) → Must confirm started; replace fluconazole
  Fluconazole → ❌ If still running - STOP; CYP3A4 interaction with tadalafil + colchicine

VASOPRESSOR:
  Noradrenaline → ✅ Maintain MAP ≥65; wean as PAH therapy takes effect

DIURETIC:
  Lasix 5mg → Very conservative; IVC 22mm suggests more room for cautious diuresis
             → Consider Lasix 10-20mg OD with daily electrolytes

URGENT ADDITIONS NEEDED:
  1. Dedicated HRCT (0.625mm) - quantify ILD extent before final ERA decision
  2. Nintedanib 150mg BD → Once infection controlled (SENSCIS trial for SSc-ILD/CTD-ILD)
     OR
     MMF 500mg BD → titrate to 1.5-3g/day (immunosuppressive for CTD-ILD)
     (Cannot start while active fungal infection)
  3. Tadalafil uptitration to 40mg → When haemodynamically stable

MONITORING:
  Daily: SpO₂, urine output, BP/HR, noradrenaline dose
  Every 48h: Lactate, troponin trend
  Weekly: NT-proBNP, CRP, LFT (ambrisentan + nintedanib both hepatotoxic)
  Every 5-7 days: Abdominal USS (splenic abscess response to antifungals)
  At 4-6 weeks: Repeat 2D echo (target RVSP falling, IVC <21mm)
  At 3 months: PFT + dedicated HRCT to quantify ILD response to therapy

Summary of the Three Reports Together

Complete Clinical Update Analysis - Mrs. K Jyothi | 15/06/2026, ~1:30 PM

Part 1: Vital Signs Interpretation

The Good News:

1. PAH therapy initiation (tadalafil → reduced RV afterload)
2. Infection treatment (micafungin + antibiotics → reduced septic vasodilation/pyrexia)
3. Cautious diuresis (furosemide → reduced RV preload)
4. Possibly the single-dose IV methylprednisolone reducing MCTD-driven vasoplegia

What Still Needs Attention:

• Tachycardia (HR 115) in PAH is dangerous. The RV in PAH depends on a slow-to-normal heart rate for adequate diastolic filling and coronary perfusion. At HR 115:
  • Diastolic time is shortened → RV filling impaired
  • Coronary perfusion pressure of the RV (which is perfused during diastole) is compromised
  • Cardiac output in RV failure is heart-rate dependent but only up to a point - above ~100-110 bpm, the loss of filling time starts reducing stroke volume
• RR 26 in CTD-ILD + PAH suggests ongoing respiratory distress - either from:
  • Pulmonary congestion (IVC still elevated from echo)
  • ILD-related reduced compliance
  • Fever-driven hyperventilation
  • Anxiety/pain
  • Metabolic compensation (is lactate still elevated?)

Part 2: The Antibiotic Regimen - Detailed Analysis

Drug 1+2: Ceftazidime-Avibactam + Aztreonam - Brilliant Combination, Important Question

The CZA + ATM Synergy Mechanism:
┌────────────────────────────────────────────────────────┐
│ CZA alone: Covers KPC + OXA-48 + ESBL + AmpC          │
│            BUT NOT MBLs (NDM, VIM, IMP)               │
│                                                         │
│ Aztreonam alone: Stable to MBL hydrolysis (NDM etc.)  │
│                  BUT broken down by ESBLs/KPC/AmpC    │
│                                                         │
│ TOGETHER: Avibactam protects aztreonam from ESBL/KPC   │
│           Aztreonam covers what CZA cannot (MBLs)      │
│           Result: covers ALL carbapenemase producers   │
│           including NDM + KPC co-producers             │
└────────────────────────────────────────────────────────┘

• Either she has a confirmed MDR/carbapenem-resistant organism isolated (Klebsiella pneumoniae NDM, Pseudomonas aeruginosa with MBL, etc.)
• Or this is empirical coverage for a patient with high risk of MDR organism (prior hospitalisation, prior carbapenem exposure, healthcare-associated infection)

1. Blood cultures (aerobic + anaerobic, x2 sets) - if not already done
2. Splenic abscess aspirate culture if any abscess enlarges to >2cm (fungal + bacterial + sensitivity)
3. Urine culture (CATH specimen)
4. BAL if there is any respiratory deterioration

Drug 3: Metronidazole - What is the Indication?

• Anaerobes (abdominal/pelvic sepsis)
• Clostridioides difficile
• Protozoa (amoeba, trichomonas)

• Fungal (most likely - given PCT <0.15, multiple small lesions) → covered by micafungin ✅
• Gram-negative bacteraemia with splenic seeding → covered by CZA + ATM ✅
• Anaerobic coverage for splenic abscess → unusual; splenic abscesses are rarely anaerobic unless associated with bowel perforation or infarcted splenic tissue

Drug 4: Vancomycin - Important Concerns

• MRSA
• Methicillin-resistant coagulase-negative Staphylococci
• Vancomycin-susceptible Enterococcus
• Gram-positive endocarditis

• MRSA bacteraemia with splenic seeding
• Line-related MRSA infection
• Gram-positive endocarditis (echo showed no vegetation ✅ - but TTE can miss small vegetations)

1. Vancomycin is itself a cause of drug fever. In up to 5-10% of patients, vancomycin causes a hypersensitivity-mediated fever that is indistinguishable from infectious fever. This typically occurs after 7-10 days of therapy. If cultures do not grow MRSA, vancomycin should be stopped - it may be contributing to the persistent fever.
2. Vancomycin nephrotoxicity - especially combined with the already hemodynamically tenuous state. Monitor vancomycin trough levels (target 15-20 mg/L for serious infections), serum creatinine daily. The IDSA now recommends AUC-guided dosing (AUC/MIC 400-600) rather than trough-only monitoring.

Drug 5: Micafungin - Correct Choice, Key Dosing Point

• Echinocandin for initial treatment ✅ (micafungin 100mg OD or caspofungin 70mg load then 50mg OD)
• Step-down to fluconazole 400mg OD after clinical stability and confirmed fluconazole-susceptible organism
• Duration: minimum 4-6 weeks, often months - until lesions resolve on imaging
• Lesions may PERSIST on imaging even with adequate treatment (granuloma formation) - do not interpret radiological persistence alone as treatment failure

Part 3: Why Fever Has Not Fully Resolved - The 5 Possible Causes

FEVER AETIOLOGY ANALYSIS:
┌─────────────────────────────────────────────────────────────┐
│ 1. HEPATOSPLENIC/SPLENIC CANDIDIASIS (Most likely primary)  │
│    - Fever classically persists 2-4 weeks despite therapy   │
│    - Granulomatous inflammation continues post-fungal death │
│    - Do NOT interpret as treatment failure                  │
│                                                             │
│ 2. MDR BACTERIAL INFECTION (Partly treated)                 │
│    - CZA + ATM coverage is appropriate                     │
│    - Fever should decline within 48-72h if bacteria covered │
│    - Cultures must confirm organism and sensitivity         │
│                                                             │
│ 3. MCTD/CTD DISEASE FLARE (Ongoing)                        │
│    - Active MCTD/Sjögren's causes fever independently       │
│    - Not controlled by antibiotics                          │
│    - HCQ + colchicine help but systemic immunosuppression   │
│      is withheld (rightly) due to active infection          │
│    - This fever will persist until infection clears and     │
│      immunosuppression can be safely resumed/escalated      │
│                                                             │
│ 4. DRUG FEVER (Active suspect)                              │
│    - Vancomycin: fever onset typically day 7-10 of therapy  │
│    - Ceftazidime: rare but possible beta-lactam fever       │
│    - Consider: fever with relative bradycardia? rash?       │
│    - Eosinophilia? (check differential count)              │
│                                                             │
│ 5. PAH-RELATED INFLAMMATORY STATE                           │
│    - Severe PAH with RV strain drives systemic inflammation │
│    - NT-proBNP 1500 = significant wall stress = cytokines  │
│    - Will improve as PAH therapy takes effect               │
└─────────────────────────────────────────────────────────────┘

• Check CBC differential - eosinophilia → drug fever
• Ask specifically: rash, flushing, or rash with vancomycin infusion? → drug fever
• If cultures negative for Gram-positive at 72-96h → trial of vancomycin withdrawal
• Trend CRP and PCT - if both falling despite ongoing fever → infection being controlled; fever is from inflammation/CTD/granuloma = do not escalate antibiotics blindly
• Serial abdominal USS at day 7 - if splenic abscesses same size or smaller → micafungin working

Part 4: PAH Medication Update - Tadalafil 40mg + Ambrisentan 2.5mg

Tadalafil 40mg ✅ - Correct Therapeutic Dose

• Systolic BP should not fall below 90 mmHg
• If BP drops further, do NOT stop tadalafil (stopping PAH therapy during RV failure is dangerous) - instead manage with careful fluid balance and reduce diuretics first

Ambrisentan 2.5mg ✅ - Appropriate Cautious Dose

• 2.5mg OD for 4-8 weeks → assess tolerability
• Uptitrate to 5mg OD → then 10mg OD (target AMBITION dose)
• Check LFTs before and after every dose increase (ERA hepatotoxicity risk)
• Monitor SpO₂ closely - ILD present; watch for worsening hypoxia

Part 5: Drug Interactions in the Current 8-Drug Regimen

Part 6: What Hydrocortisone Status?

1. Vasopressor-dependent state → CIRCI (Critical Illness-Related Corticosteroid Insufficiency)
2. Prior steroid exposure → adrenal axis suppression

• Full stress-dose (200mg/day) is no longer strictly indicated
• However, do NOT abruptly stop steroids - taper:
  • Reduce to hydrocortisone 50mg TDS (150mg/day) for 48h
  • Then 50mg BD (100mg/day) for 48h
  • Then 25mg BD (50mg/day) for 48h - physiological replacement
  • Then stop (or convert to oral prednisolone 5mg OD as background MCTD maintenance once infection settles)

Part 7: What Needs to Happen Next - Priority Order

IMMEDIATE (today):
1. Serum lactate - confirm it is falling from 2.5
2. Vancomycin trough level - ensure 15-20 mg/L; check daily creatinine
3. CBC differential count - look for eosinophilia (drug fever screen)
4. CRP + PCT trend (expect CRP falling; PCT should remain <0.5 if fungal)
5. Blood glucose (hydrocortisone still running - hyperglycaemia risk)
6. Hydrocortisone taper - start reducing dose now noradrenaline is stopped

WITHIN 24-48 HOURS:
7. Culture results review - if Gram-positive absent → trial vancomycin stop
8. LFTs - ambrisentan + metronidazole + prior MCTD hepatic involvement
9. Blood cultures sensitivity result → de-escalate CZA+ATM if possible
10. Serial abdominal USS (day 7 from start of micafungin) → splenic abscess response
11. Ask: Has metronidazole a specific confirmed indication? If not, consider stopping

WITHIN 3-5 DAYS:
12. Repeat 2D echo if HR persists >100 or lactate not clearing
13. NT-proBNP + troponin repeat → PAH therapy response assessment
14. Consider: Is HR 115 from PAH, fever, anaemia, or beta-blocker need?
    (Caution: beta-blockers are CONTRAINDICATED in Group 1 PAH - 
     DO NOT give beta-blockers for tachycardia in PAH)

ONCE INFECTION CONTROLLED (2-4 weeks):
15. Start MMF 500mg BD → titrate to 1.5-2g/day (CTD-ILD treatment)
16. Ambrisentan uptitration 2.5 → 5 → 10mg
17. Consider nintedanib 150mg BD for ILD-fibrotic component
18. APLA panel, anti-Jo1, anti-MDA5 (still pending from original list)

Summary Scorecard - Progress Today